Company* (Country; Symbol) |
Product |
Description |
Indication |
Status (Date) |
CANCER | ||||
Abraxis BioScience Inc. (ABBI) |
Abraxane (FDA-approved) |
Paclitaxel protein-bound particles for injectable suspension |
Metastatic breast cancer |
Phase II showed 150mg/m2 of Abraxane administered weekly and 300 mg/m2 every three weeks resulted in longer progression-free survival and an overall improved toxicity profile compared to 100 mg/m2 of Taxotere every three weeks (6/4) |
Abraxis BioScience Inc. (ABBI) |
Nab-paclitaxel |
Albumin-bound paclitaxel |
Non-squamous non-small-cell lung cancer and platinum-sensitive, recurrent ovarian, peritoneal and fallopian tube cancer |
Phase II studies of nab-paclitaxel in combination with Avastin and carboplatin showed that 31.3% of 36 patients had a partial response and 52.1% had stable disease (6/5) |
Adherex Technologies Inc. (AMEX:ADH) |
ADH-1 |
Single-agent therapy |
N-cadherin positive solid tumors |
Phase II showed it was well tolerated and prolonged stable disease (6/4) |
AEterna Zentaris Inc. (AEZS) |
AEZS-108 |
Targeted cytotoxic luteinizing hormone-releasing hormone analogue |
Cancers expressing LHRH receptors |
Phase I showed evidence of antitumor activity (6/4) |
Agennix Inc.* |
Talactoferrin alfa |
Oral immunomodulatory protein |
Refractory non-small-cell lung cancer |
Phase II met its primary endpoint of a statistically significant improvement in overall survival (6/4) |
Alexion Pharmaceuticals Inc. (ALXN) |
Soliris (FDA-approved) |
Eculizumab |
Paroxysmal nocturnal hemo-globinuria in patients with aplastic anemia or myelodysplastic syndromes |
Phase III showed it significantly reduced red blood cell destruction, decreased blood transfusion requirements, improved fatigue and quality-of-life outcomes, and reduced thrombotic events (6/4) |
Antisoma plc (UK; LSE:ASM) |
ASA404 |
A small-molecule vascular disrupting agent |
Hormone-refractory prostate cancer |
Phase II showed a response rate of 59% for ASA404 plus docetaxel vs. 37% for docetaxel alone (6/4) |
Ariad Pharmaceuticals Inc. (ARIA) |
AP23573 |
mTOR inhibitor |
Metastatic endometrial cancer |
Phase II demonstrated efficacy (6/4) |
ArQule Inc. (ARQL) |
ARQ197 |
Selective inhibitor of the c-Met receptor tyrosine kinase |
Cancer |
Phase I data showed it was well tolerated over extended dosing periods (6/4) |
Biogen Idec Inc. (BIIB) |
Zevalin (FDA-approved) |
Ibritumomab tiuxetan radioimmunotherapy |
Follicular lymphoma |
Phase II showed it doubled the rate of complete response compared to standard treatment (6/4) |
Celator Pharmaceuticals Inc.* |
CPX-1 |
Irinotecan HCl: Floxouridine |
Advanced solid tumors |
Phase I showed safety and 73% of patients had a clinical benefit (6/4) |
Celgene Corp. (CELG) |
Revlimid (FDA-approved) |
Lenalidomide |
Multiple myeloma |
Phase III data showed using Revlimid with a reduced dose of dexamethasone resulted in a 98% survival rate in patients younger than 65 compared to 90% with Revlimid and high-dose dexamethasone (6/5) |
Celtic Pharma* and Neurobiological Technologies Inc. (NTII) |
Xerecept |
Corticorelin acetate injection |
Peritumoral edema |
Phase III data showed that long-term therapy appears safe and well tolerated, and is associated with reduced exposure to dexamethasone overall, resolution or improvement in associated steroid side effects and neurological stability or improvement (6/5) |
Cell Genesys Inc. (CEGE) and Medarex Inc. (MEDX) |
GVAX and MDX-010 |
Immunotherapy and a fully human anti-CTLA-4 antibody |
Advanced prostate cancer |
Phase I demonstrated antitumor activity in five patients (6/4) |
| ||||
Cell Genesys Inc. (CEGE) |
GVAX |
Immunotherapy |
Pancreatic cancer |
Phase II data show a median disease-free survival of about 16 months (6/4) |
Cell Therapeutics Inc. (CTIC) |
Xyotax |
Paclitaxel poliglumex |
Advanced non-small-cell lung cancer |
Cooperative group data showed E2 levels in serum are prognostic in men and women, showing those with higher levels have shorter survival (6/4) |
Celldex Therapeutics Inc. (BE:C4W) |
CDX-1307 |
Intrademerally administered |
Cancer |
Phase I suggests CDX-1307 resulted in localization of the beta subunit of human chorionic gonadotropin in antigen-presenting cells of the skin (6/4) |
Celldex Therapeutics Inc. (BE:C4W) |
CDX-110 |
Immunotherapy that targets EGFRvIII |
Glioblastoma multiforme |
Phase II data shows a median survival time of 126.1 weeks, and a median time to progression of 64.5 weeks vs. a control's median of 28.52 weeks (6/4) |
ChemGenex Pharmaceuticals Ltd. (Australia; ASX:CXS) |
Quinamed |
Amonafide dihydrochloride |
Solid tumors |
Phase I/IIa data showed the dose level could be optimized and the drug was well tolerated (6/4) |
Cougar Biotechnology Inc. (OTC BB:CGRB) |
CB7630 |
Abiraterone acetate |
Prostate cancer |
Interim Phase I/II data showed 65% of patients had a decline in PSA levels of greater than 50% (6/4) |
Cyclacel Pharmaceuticals Inc. (CYCC) |
CYC682 |
Sapacitabine; an oral nucleoside analogue |
Acute myelogenous leukemia and myelodysplastic syndromes |
Phase I data showed 11 of 21 patients had a decrease of more than 50% in bone marrow blasts (6/4) |
Cytogen Corp. (CYTO) |
Quadramet (FDA-approved) |
Samarium Sm-153 lexidronam injection |
Prostate cancer |
Phase I showed it can be safely administered (6/4) |
Cytokinetics Inc. (CYTK) |
Ispinesib |
Kinesin spindle protein inhibitor |
Advanced kidney cancer |
Phase II showed the dose of 7 mg/m2 on days one, eight and 15 every 28 days does not lead to objective responses but is well tolerated (6/4) |
Cytokinetics Inc. (CYTK) |
SB-743921 |
Small-molecule kinesin spindle protein inhibitor |
Cancer |
Phase I data showed it is well tolerated (6/4) |
Diatos SA* (France) |
DTS-201 |
Doxorubicin prodrug |
Cancer |
Phase I demonstrated safety, tolerability and the ability to deliver high doses (6/4) |
Eli Lilly & Co. |
Altima |
Pemetrexed for injection |
Non-small-cell lung cancer |
Phase III of Altima plus carbo-platin showed comparable quality of life benefit along with reduced toxicity vs. Gemzar plus carboplatin (6/4) |
EntreMed Inc. (ENMD) |
Panzem |
2-methoxyestradiol |
Multiple myeloma; glioblastoma multiforme |
Phase II demonstrated prolonged stable disease and minor responses (6/4); Phase II resulted in one partial response and seven stable diseases (6/5) |
Exelixis Inc. (EXEL) |
XL999 |
Tyrosine kinase inhibitor |
Non-small-cell lung cancer, renal cell carcinoma, metastatic colorectal cancer, recurrent ovarian cancer, acute myelogenous leukemia and multiple myeloma |
Six Phase II trials showed preliminary antitumor activity in patients with lung cancer and AML, as well as a cardiovascular adverse event profile consistent with previously reported data (5/4) |
Exelixis Inc. (EXEL) |
XL880 |
A small molecule that inhibits MET and VEGFR2 |
Cancer |
Phase I data showed it produced five partial responses and prolonged stable disease of more than three months (6/4) |
Favrille Inc. (FVRL) |
Favid |
Patient-specific immunotherapy |
Indolent B-cell non-Hodgkin's lymphoma |
Phase II of FavId in combination with maintenance Rituxan showed it is feasible and well tolerated (6/4) |
Genentech Inc. (NYSE:DNA) |
Avastin (FDA-approved) |
Bevacizumab; antibody drug |
Advanced non-small-cell lung cancer |
A 1,044-patient study demonstrated that Avastin significantly increased progression-free survival at two doses in combination with chemotherapy, but the lesser dose showed a greater improvement (6/4) |
Genentech Inc. (NYSE:DNA) |
Avastin (FDA-approved) |
Bevacizumab; antibody drug |
Metastatic renal cell carcinoma |
Phase III of the drug in combination with interferon alpha-2a showed positive results in progression-free survival (6/4) |
Genentech Inc. (NYSE:DNA) |
Herceptin (FDA-approved) |
Trastuzumab |
HER2-positive breast cancer |
Phase III showed the addition of Herceptin to standard adjuvant therapy significantly improved overall survival (6/4) |
Genentech Inc. (NYSE:DNA) |
Pertuzumab |
A monoclonal antibody designed to bind to the HER2 receptor |
Platinum-resistant ovarian, fallopian tube or primary peritoneal cancers |
Phase II demonstrated an increase in overall progression-free survival by 52% when combined with gemcitabine (6/4) |
Genentech Inc. (NYSE:DNA) |
Pertuzumab |
A monoclonal antibody designed to bind to the HER2 receptor |
Metastatic breast cancer |
Phase II showed encouraging results in objective response rates (6/4) |
Genentech Inc. (NYSE:DNA) |
Apomab |
Human DR5 agonist antibody |
Solid tumors or non-Hodgkin's lymphoma |
Phase I showed the product was well tolerated at the five dose levels tested (6/4) |
Genta Inc. (GNTA) |
Ganite (FDA-approved) |
Gallium nitrate |
Non-Hodgkin's lymphoma |
Phase II of Ganite plus Rituxan and dexamethasone produced a major objective response in 41% of patients (6/4) |
GlaxoSmithKline plc (UK) |
Tykerb |
Oral small-molecule HER2 kinase inhibitor |
Advanced breast cancer |
Three studies were positive: one with paclitaxel, one with heavily pretreated patients with CNS metastases and one with cape-citabine (6/4) |
GlaxoSmithKline plc (UK) and Antigenics Inc. (AGEN) |
MAGE-A3 ASCI |
A purified recombinant MAGE-A3 protein combined with GSK's adjuvant system containing the QS-21 Stimulon adjuvant from Antigenics |
Lung cancer |
Opening patient recruitment in a Phase III study (6/5) |
Gloucester Pharmaceuticals Inc.* |
Romidepsin |
A histone deaceytlase inhibitor |
Cutaneous and peripheral T-cell lymphoma |
Interim Phase II data showed four of 70 patients achieved a complete response (6/5) |
GPC Biotech AG (GPCB), Pharmion Corp. (PHRM) and Spectrum Pharmaceuticals Inc. (SPPI) |
Satraplatin |
Platinum-based drug; oral compound |
Hormone-refractory prostate cancer |
Phase III data show it reduces disease progression by 33% compared to control (6/4) |
GPC Biotech AG (Germany; GPCB), Pharmion Corp. (PHRM) and IDM Pharma Inc. (IDMI) |
Uvidem |
Melanoma vaccine |
Melanoma |
Phase II data showed it was well tolerated, and had evidence of efficacy and induction of immune response (6/5) |
IDM Pharma Inc. (IDMI) |
EP-2101 |
Vaccine |
Non-small-cell lung cancer |
Phase II showed it is well tolerated and suggested a survival benefit (6/4) |
ImClone Systems Inc. (IMCL) and Bristol-Myers Squibb Co. |
Erbitux (FDA-approved) |
IgG1 monoclonal antibody |
Colorectal cancer (untreated) |
Data showed the drug slightly prolonged survival from 8 months to 8.9 months (6/4) |
ImClone Systems Inc. (IMCL) |
IMC-A12 |
A monoclonal antibody targeted to IGF-1R (insulin-like growth factor type 1 receptor) |
Advanced solid tumors |
First-in-human results showed it was well tolerated and had activity in patients (6/5) |
ImmunoGen Inc. (IMGN) |
huN901-DM1 |
Tumor-Activated Prodrug; trastuzumab |
Small-cell lung cancer |
Four of 10 patients had an objective response in a Phase I (6/4) |
Immunomedics Inc. (IMGN) |
Epratuzumab |
Humanized anti-CD20 monoclonal antibody |
Non-Hodgkin's lymphoma |
Phase I/II showed it was active at a low dose; the overall objective response was 45% (6/4) |
Infinity Pharmaceuticals Inc. (INFI) and MedImmune Inc.(LSE:MDI) |
IPI-504 |
A heat-shock protein 90 inhibitor |
Gastrointestinal stromal tumors and other advanced soft-tissue sarcomas |
Phase I showed 81% of treated patients achieved stable disease or better (6/5) |
Innovive Pharmaceuticals Inc. (OTC BB:IVPH) |
INNO-406 |
A dual Bcr-Abl and Lynkinase inhibitor |
Gleevec-resistant chronic myelogenous leukemia |
Phase I showed it was well tolerated and generated hematologic, cytogenic and molecular responses (6/4) |
Introgen Therapeutics Inc. (INGN) |
Advexin |
Adenoviral vector containing the p53 tumor suppressor gene |
Recurrent squamous cell carcinoma of the head and neck |
Phase II showed a significant correlation between abnormal p53, tumor responses and increased survival following Advexin (6/4) |
Keryx Biopharmaceuticals Inc. (KERX) and AEterna Zentaris Inc. (AEZS) |
Perifosine |
Oral agent that modulates AKT and other signal transduction pathways |
Advanced sarcoma |
Phase I and II data showed an overall clinical benefit rate of 52% (6/4) |
Kosan Biosciences Inc. (KOSN) |
KOS-953 |
Tanespimycin; HSP90 inhibitor |
Metastatic melanoma and multiple melanoma |
Phase II demonstrated antitumor activity and tolerability; combined with bortezomib, it showed a high degree of antitumor activity |
Kosan Biosciences Inc. (KOSN) |
KOS-1584/R16545 |
An epothilone |
Solid tumors |
Phase I demonstrated activity in 13 of 41 evaluable patients |
| ||||
Kosan Biosciences Inc. (KOSN) |
Alvespimycin |
A second-generation Hsp90 inhibitor |
Refractory Her2-positive metastatic breast cancer and refractory ovarian cancer |
Phase I data showed promising antitumor activity and tolerability in combination with Herceptin (6/4) |
Medarex Inc. (MEDX) and Bristol-Myers Squibb Co. |
MDX-010 |
Ipilimumab; and antibody that binds to CTLA-4 |
Advanced melanoma |
Multiple studies demonstrated an antitumor response, either as a monotherapy or in combination with other therapies (6/5) |
MGI Pharma Inc. (MOGN) |
Dacogen (FDA-approved) |
Decitabine for injection; a hypomethylating agent |
Acute myelogenous leukemia; acute lymphocytic leukemia |
Data showed an overall response rate ranging from 50% to 57% across three clinical trials; Phase I data showed that two of seven patients had complete bone marrow response (6/5) |
MGI Pharma Inc. (MOGN) |
Aloxi (FDA-approved) |
Palonosetron hydrochloride injection |
Solid tumors |
The drug in combination with dexamethasone and aprepitant demonstrated a complete response in 75% of patients on day one (6/5) |
MGI Pharma Inc. (MOGN) |
Irofulven |
Hydroxymethylacylfulvene; compound from acylfulvenes family |
Hormone-refractory prostate cancer |
Phase II data demonstrated a trend toward increased survival (6/5) |
Micromet Inc. (MITI) |
MT201 |
Adecatumumab |
Metastatic breast cancer |
Phase II showed a significant prolongation of time to progression in the higher dose group compared to a lower dose (6/4) |
Millenium Pharmaceuticals Inc. (MLNM) |
Velcade (FDA-approved) |
Bortezomib |
Multiple myeloma |
A regimen that employs Velcade, called Total Therapy 3, generated a complete response and near-complete response rate of 84% when used prior to and as maintenance following stem cell transplantation; other data showed the combination of Velcade and Doxil improves the probability of survival by 41% (6/4) |
Millennium Pharmaceuticals Inc. (MLNM) |
Velcade (FDA-approved) |
Bortezomib |
B-cell lymphoma and mantle cell lymphoma |
The addition of Velcade to R-CHOP produced high complete response rates of 83%; (6/4) |
Millennium Pharmaceuticals Inc. (MLNM) |
MLN8054 |
Aurora A kinase inhibitor |
Cancer |
Phase I data showed six patients maintained stable disease for longer than eight months (6/4) |
Novacea Inc. (NOVC) |
Asentar |
DN-101; oral, intermittent, high-dose of calcitriol designed to activate the vitamin D receptor |
Non-small-cell lung cancer |
Phase I/II showed tolerability; it did not reach the maximum tolerated dose (6/4) |
OncoGenex Technologies Inc.* |
OGX-011 |
Second-generation anti-sense drug designed to inhibit the production of clusterin, a cell-survival protein |
Non-small-cell lung cancer |
Phase I/II showed a median over-all survival of 14 months compared to eight to 11 months for chemotherapy alone and 12.3 months for Avastin plus chemo (6/4) |
Onyx Pharmaceuticals Inc. (ONXX) and Bayer Healthcare Pharmaceuticals Inc. |
Nexavar (FDA-approved) |
Sorafenib; oral multi-kinase inhibitor |
Liver cancer |
Phase III data showed the drug improves survival; median over-all survival was 10.7 months vs. 7.9 months in the placebo group (6/4) |
OSI Pharmaceuticals Inc. (OSIP) |
Tarceva (FDA-approved) |
Erlotinib; small-molecule HER1/EGFR inhibitor |
Non-small-cell lung cancer |
Phase I established a maximum tolerated dose of 300 mg per day; Phase II data suggested a correlation between skin rash development and severity and treatment outcome in patients with Stage IIIb and Stage IV NSCLC (6/5) |
Oxford BioMedica plc (UK; LSE:OXB) and Sanofi-aventis (France) |
Trovax |
Immunotherapy |
Metastatic renal cell cancer |
Phase II on 48 evaluable patients showed it was well tolerated and induced anti-5T4 antibody responses in 91% of patients (6/4) |
Pfizer Inc. |
Sutent (FDA-approved) |
Sunitinib malate; a multi-kinase inhibitor |
Advanced renal cell carcinoma |
Phase III data showed prolonged progression-free survival across all patient risk groups (6/4) |
Pharmacyclics Inc. (PCYC) |
Xcytrin |
Motexafin gadolinium |
Metastatic non-small-cell lung cancer |
Phase II showed comparable response rates and survival to approved second-line therapies (6/4) |
Pharmion Corp. (PHRM) |
Amrubicin |
A third-generation synthetic anthracycline |
Platinum-sensitive small-cell lung cancer |
Phase II showed that 40% of 15 patients had an objective tumor response (6/4) |
Pharmion Corp. (PHRM) |
Thalidomide |
Revlimid is a derivative of Thalomid (thalidomide) |
Multiple myeloma |
Phase III data shows it improves overall survival by 17.6 months (6/4) |
Pharmion Corp. (PHRM) |
Vidaza (FDA-approved) |
Azacitidine |
Hematologic malignancies and advanced solid tumors |
61% of myelodysplastic syndrome patients experienced hematologic improvement and combining it with valproic acid is safe and active in advanced solid tumors (6/4) |
Pharmion Corp. (PHRM) and MethylGene Inc. (Canada; TSX:MYG) |
MGCD0103 |
Isotype selective histone deacetylase inhibitor |
Hodgkin's lymphoma, myelodysplastic syndromes and acute myelogenous leukemia |
Phase II and I/II data showed significant antitumor activity (6/4) |
Poniard Pharmaceuticals Inc. (PARD) |
Picoplatin |
New-generation platinum therapy |
Recurrent small-cell lung cancer |
Phase II demonstrated a survival benefit (6/4) |
| ||||
PTC Therapeutics Inc.* |
PTC299 |
A VEGF inhibitor |
Cancer |
Phase I showed it was well tolerated (6/4) |
| ||||
Regeneron Pharmaceuticals Inc. (REGN) |
VEGF Trap |
Aflibercept; an angiogenic agent |
Ovarian cancer |
Phase II data showed an 8% partial response rate and 77% achievement of stable disease in heavily pretreated patients who have failed multiple other treatments (6/4) |
SciClone Pharmaceuticals Inc. (SCLN) and Sigma-Tau SpA |
Zadaxin |
Thymosin alpha 1 |
Stage IV malignant melanoma |
Phase II achieved its primary endpoint; in combination with dacarbazine, it tripled the overall response rate and extended over-all survival by nearly three months (6/4) |
Synta Pharmaceuticals Corp. (SNTA) |
STA-4783 |
Small molecule |
Metastatic melanoma |
Phase IIb data of STA-4783 in combination with paclitaxel showed a median survival of 12 months compared to 7.8 months for those who initially received paclitaxel alone (6/5) |
Tapestry Pharmaceuticals Inc. (TPPH) |
TPI 287 |
Next-generation taxane agent |
Cancer |
Two Phase I studies showed it was safe and well tolerated (6/4) |
Transave Inc.* |
Cisplatin |
Sustained-release liposomal inhalation-targeting agent |
Relapsed/progressive osteosarcoma |
Phase Ib/IIa showed it was safe and well tolerated, and responses suggestive of antitumor activity were observed (6/4) |
Vical Inc. (VICL) |
Intratumoral delivery of plasmid DNA encoding interleukin-2 |
Melanoma tumors |
Phase I showed the delivery followed by electroporation, was administered safely following sedative premedication (6/4) |
|
Vion Pharmaceuticals Inc.(VION) |
Cloretazine |
VNP40101M; single agent |
Refractory small-cell lung cancer |
Phase II led to partial responses in six of 20 evaluable patients in the sensitive relapse arm (6/4) |
Xanthus Pharmaceuticals Inc.* |
Xanafide |
A topoisomerase II inhibitor |
Acute myeloid leukemia |
Phase II indicated that 44% of patients achieved complete remission with or without complete hematopoietic recovery (6/4) |
Ziopharm Oncology Inc. (ZIOP) |
ZIO-101 |
Darinaparsin |
Advanced multiple myeloma |
Phase I/II showed four of 10 evaluable patients achieved stable disease of more than four months; treatment was well tolerated (6/4) |
ZymoGenetics Inc. (ZGEN) |
Atacicept |
Formerly TACI-Ig |
B-cell chronic lymphocytic leukemia |
Interim Phase Ib data showed it was well tolerated and biologically active at all dose levels (6/4) |
Notes: | ||||
* Privately held. | ||||
Unless otherwise noted, the stock symbols listed for public companies are on the Nasdaq market. | ||||
AMEX = American Stock Exchange; ASX = Australian Stock Exchange; BE = Berlin Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSX = Toronto Stock Exchange. | ||||
